Patents by Inventor Lance E. Steward

Lance E. Steward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ACTIVATING CLOSTRIDIAL TOXINS
    Publication number: 20130281666
    Abstract: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.
    Type: Application
    Filed: April 30, 2013
    Publication date: October 24, 2013
    Inventors: Marc F. Verhagen, Dean G. Stathakis, Lance E. Steward
  • DEGRADABLE CLOSTRIDIAL TOXINS
    Publication number: 20130273633
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Application
    Filed: March 18, 2013
    Publication date: October 17, 2013
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • Methods of intracellular conversion of single-chain proteins into their di-chain form
    Patent number: 8546108
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Grant
    Filed: January 24, 2011
    Date of Patent: October 1, 2013
    Assignee: Allergan, Inc.
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
  • METHODS OF ACTIVATING CLOSTRIDIAL TOXINS
    Publication number: 20130245227
    Abstract: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.
    Type: Application
    Filed: May 31, 2013
    Publication date: September 19, 2013
    Applicant: Allergan, Inc.
    Inventors: Marc F. Verhagen, Dean G. Stathakis, Lance E. Steward
  • Lipophilic dye-based FRET assays for clostridial toxin activity
    Patent number: 8535941
    Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: September 17, 2013
    Assignee: Allergan, Inc.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
    Patent number: 8518417
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: July 11, 2007
    Date of Patent: August 27, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Degradable clostridial toxins
    Patent number: 8512992
    Abstract: The specification discloses Clostridial toxins or Clostridial toxin chimeras comprising an inactivation cleavage site, polynucleotide molecules encoding such toxins or chimeras, compositions comprising such toxins or chimeras, and method of producing such toxins or chimeras.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: August 20, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Sanjiv Ghanshani, Ester Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Kei Roger Aoki
  • MODIFIED CLOSTRIDIAL TOXINS WITH ENHANCED TRANSLOCATION CAPABILITY AND ENHANCED TARGETING ACTIVITY
    Publication number: 20130203148
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an enhanced targeting domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: July 11, 2007
    Publication date: August 8, 2013
    Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
  • Methods of Treating Cancer Using Growth Factor Retargeted Endopeptidases
    Publication number: 20130195838
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: August 9, 2012
    Publication date: August 1, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. JACKY, Patton E. Garay, Yanira Molina, Dean G. Stathakis, Joseph Francis, Kei Roger Aoki, Ester Fernandez-Salas, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt
  • Methods of activating clostridial toxins
    Patent number: 8486422
    Abstract: The specification discloses modified Clostridial toxins comprising an exogenous Clostridial toxin di-chain loop protease cleavage site located within the di-chain loop region; polynucleotide molecules encoding such modified Clostridial toxins; method of producing such modified Clostridial toxins, method of activating such modified Clostridial toxins and methods of activating recombinantly-expressed Clostridial toxins.
    Type: Grant
    Filed: June 27, 2008
    Date of Patent: July 16, 2013
    Inventors: Marc F. Verhagen, Dean G. Stathakis, Lance E. Steward
  • Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
    Patent number: 8460682
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: June 11, 2013
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Methods Of Intracellular Conversion Of Single-Chain Proteins Into Their Di-Chain Form
    Publication number: 20120295330
    Abstract: The present specification discloses expression constructs comprising single-chain proteins comprising a di-chain loop region comprising an exogenous protease cleavage site and a protease that can cleave the exogenous protease cleavage site located within the di-chain loop, cell compositions comprising such expression construct, and intracellular methods of converting the single-chain protein into its di-chain form.
    Type: Application
    Filed: January 24, 2011
    Publication date: November 22, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Sanjiv Ghanshani, Linh Q. Le, Yi Liu, Lance E. Steward
  • Neurotoxins with enhanced target specificity
    Patent number: 8309686
    Abstract: Modified neurotoxins that contain protease cleavage sites susceptible uniquely to proteases present in certain tissues are described. The toxins can be selectively activated by proteases in muscle or selectively inactivated by proteases in blood.
    Type: Grant
    Filed: September 18, 2008
    Date of Patent: November 13, 2012
    Assignee: Allergan, Inc.
    Inventors: Wei-Jen Lin, Kei Roger Aoki, Lance E. Steward
  • Multivalent clostridial toxins
    Patent number: 8273865
    Abstract: The present invention is directed to multivalent Clostridial toxin comprising more than one binding domain directed to a cell surface molecule of a target cell. Such modified toxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions may be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
  • Activatable clostridial toxins
    Patent number: 8273358
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: September 25, 2012
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • LIPOPHILIC DYE-BASED FRET ASSAYS FOR CLOSTRIDIAL TOXIN ACTIVITY
    Publication number: 20120231538
    Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that comprises a membrane-associated Clostridial toxin substrate comprising a first member of a fluorescence resonance energy transfer pair; and a Clostridial toxin recognition sequence including a cleavage site; and a membrane-associated second member of the FRET pair and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.
    Type: Application
    Filed: February 27, 2012
    Publication date: September 13, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
  • Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
    Publication number: 20120207734
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
    Publication number: 20120207743
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a disease or disorder associated with aberrant new blood vessel formation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
    Publication number: 20120207733
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer or a disease of hyperproliferation in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, Kei Roger Aoki, Ester Fernandez-Salas
  • Treatments Using PSMA Ligand Endopeptidases
    Publication number: 20120207742
    Abstract: The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating a prostate cancer, a benign prostatic hyperplasia, and/or neovascularization or pathological angiogenesis associated with a cancer in a mammal using such TVEMP compositions.
    Type: Application
    Filed: February 13, 2012
    Publication date: August 16, 2012
    Applicant: ALLERGAN, INC.
    Inventors: Birgitte P.S. Jacky, Patton E. Garay, Yanira Molina, Joseph Francis, Lance E. Steward, Sanjiv Ghanshani, Terrence J. Hunt, George Sachs, Kei Roger Aoki, Ester Fernandez-Salas